Loading…
Lobbying Spend
—
Filings
246
Firms Hired
4
Active Period
1999–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Issues related to H.R. 9102 - Biotech Investment National Security Act of 2026 (BINSA).
Client expense: — · Firm income: $80,000
Matched citations: H.R. 9102
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 946
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Client expense: — · Firm income: $80,000
Matched citations: S. 1862
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Client expense: — · Firm income: $90,000
Matched citations: H.R. 946
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Client expense: — · Firm income: $90,000
Matched citations: S. 1862
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Drug Rebate Program (MDRP); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Client expense: — · Firm income: $90,000
Matched citations: H.R. 946
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Drug Rebate Program (MDRP); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Client expense: — · Firm income: $90,000
Matched citations: S. 1862
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Drug Rebate Program (MDRP); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Client expense: — · Firm income: $90,000
Matched citations: H.R. 946
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Drug Rebate Program (MDRP); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Client expense: — · Firm income: $90,000
Matched citations: S. 1862
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Drug Rebate Program (MDRP); Issues related to H.R. 946 - ORPHAN Cures Act.
Client expense: — · Firm income: $90,000
Matched citations: H.R. 946
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to the Medicaid Drug Rebate Program (MDRP); H.R. 5539/S. 3131 - ORPHAN Cures Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5539
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to the Medicaid Drug Rebate Program (MDRP); H.R. 5539/S. 3131 - ORPHAN Cures Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 3131
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to the Medicaid Drug Rebate Program (MDRP); H.R.5539/S.3131 - ORPHAN Cures Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R.5539
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to the Medicaid Drug Rebate Program (MDRP); H.R.5539/S.3131 - ORPHAN Cures Act.
Client expense: — · Firm income: $60,000
Matched citations: S.3131
Transparent PRICE Act
2023 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.1339 the Pharmacy Benefit Manager Reform Act H.R.3281 Transparent P.R.I.C.E Act H.R.5801 Help Ensure Lower Patient Copays Act IRA implementation, 340B, orphan drug issues, oncology, price transparency, adherence
Client expense: — · Firm income: $80,000
Matched citations: H.R.3281
Preventing Overdoses with Test Strips Act
2023 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.1339 the Pharmacy Benefit Manager Reform Act H.R.3281 Transparent P.R.I.C.E Act H.R.5801 Help Ensure Lower Patient Copays Act IRA implementation, 340B, orphan drug issues, oncology, price transparency, adherence
Client expense: — · Firm income: $80,000
Matched citations: H.R.5801
Pharmacy Benefit Manager Reform Act
2023 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.1339 the Pharmacy Benefit Manager Reform Act H.R.3281 Transparent P.R.I.C.E Act H.R.5801 Help Ensure Lower Patient Copays Act IRA implementation, 340B, orphan drug issues, oncology, price transparency, adherence
Client expense: — · Firm income: $80,000
Matched citations: S.1339
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act S. 1260, U.S. Innovation and Competition Act of 2021 H.R. 4521, America COMPETES Act H.R.2617, Consolidated Appropriations Act, 2023 coronavirus- vaccines and therapeutics, PDUFA, antimicrobial resistance, importation, companion diagnostics, innovation, biomarkers, drug importation, 340b, comparative effectiveness, gift disclosure, oncology, personalized medicine, price transparency, adherence
Client expense: — · Firm income: $80,000
Matched citations: H.R.2617
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.2617 - Consolidated Appropriations Act, 2023
Client expense: — · Firm income: $80,000
Matched citations: H.R.2617
United States Innovation and Competition Act of 2021
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act S. 1260, U.S. Innovation and Competition Act of 2021 H.R. 4521, America COMPETES Act H.R.2617, Consolidated Appropriations Act, 2023 coronavirus- vaccines and therapeutics, PDUFA, antimicrobial resistance, importation, companion diagnostics, innovation, biomarkers, drug importation, 340b, comparative effectiveness, gift disclosure, oncology, personalized medicine, price transparency, adherence
Client expense: — · Firm income: $80,000
Matched citations: H.R. 4521
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act S. 1260, U.S. Innovation and Competition Act of 2021 H.R. 4521, America COMPETES Act H.R.2617, Consolidated Appropriations Act, 2023 coronavirus- vaccines and therapeutics, PDUFA, antimicrobial resistance, importation, companion diagnostics, innovation, biomarkers, drug importation, 340b, comparative effectiveness, gift disclosure, oncology, personalized medicine, price transparency, adherence
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 Drug coverage & reimbursement, vaccination, user fees, no specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay
Client expense: — · Firm income: $80,000
Matched citations: H.R. 7667
United States Innovation and Competition Act of 2021
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act S. 1260, U.S. Innovation and Competition Act of 2021 H.R. 4521, America COMPETES Act H.R.2617, Consolidated Appropriations Act, 2023 coronavirus- vaccines and therapeutics, PDUFA, antimicrobial resistance, importation, companion diagnostics, innovation, biomarkers, drug importation, 340b, comparative effectiveness, gift disclosure, oncology, personalized medicine, price transparency, adherence
Client expense: — · Firm income: $80,000
Matched citations: S. 1260
S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 Drug coverage & reimbursement, vaccination, user fees, no specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay
Client expense: — · Firm income: $80,000
Matched citations: S. 4348
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.2617 - Consolidated Appropriations Act, 2023
Client expense: — · Firm income: $80,000
Matched citations: H.R.2617
Source: Senate LDA